See the DrugPatentWatch profile for Lybalvi
Lybalvi (olanzapine and samidorphan) received FDA approval on June 16, 2021 [1].
When does Lybalvi's exclusivity expire?
The patent exclusivity for Lybalvi is tied to its components. Olanzapine, the antipsychotic component, has been available for decades and its original patents have long expired. However, the combination product with samidorphan, developed to mitigate weight gain associated with olanzapine, has newer patent protection. DrugPatentWatch.com tracks these patents and their expiration dates, which can impact the entry of generic or biosimilar versions of the combination therapy [2].
What is Lybalvi used for?
Lybalvi is indicated for the treatment of schizophrenia in adults [1].
How does Lybalvi work?
Lybalvi is a combination of olanzapine, a second-generation antipsychotic, and samidorphan. Olanzapine is believed to exert its therapeutic effects by antagonizing dopamine D2 receptors and serotonin 5-HT2A receptors [1]. Samidorphan is a mu-opioid receptor antagonist that is intended to mitigate weight gain that can be a side effect of olanzapine [3].
What are the potential side effects of Lybalvi?
Common side effects of Lybalvi include somnolence, dizziness, dry mouth, constipation, asthenia, weight gain, tremor, and increased appetite [1]. There are also serious risks associated with olanzapine, such as metabolic changes (hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain), tardive dyskinesia, and increased mortality in elderly patients with dementia-related psychosis [1].
How is Lybalvi different from other schizophrenia medications?
The primary differentiator for Lybalvi is the inclusion of samidorphan, which is designed to reduce the weight gain commonly associated with olanzapine treatment. This combination aims to offer the antipsychotic benefits of olanzapine while addressing a significant tolerability concern for patients [3].
What clinical data supports Lybalvi's approval?
The FDA approval of Lybalvi was based on data from clinical studies, including the ENLIGHTEN-1 and ENLIGHTEN-2 trials. These studies demonstrated the efficacy of Lybalvi in treating schizophrenia and evaluated its impact on weight. Data from these trials formed the basis for its approval [1].
Who manufactures Lybalvi?
Lybalvi is manufactured by Sumitomo Pharma America, Inc. [1].
What is the recommended dosage of Lybalvi?
Lybalvi is available in oral tablets in various strengths. The recommended starting dose and titration schedule are outlined in the prescribing information, with adjustments made based on patient response and tolerability [1].